About Invitae
Invitae is a publicly listed company based in San Francisco (United States) founded in 2010 by Michele Cargill and Sean Emerson George. Home-based genetic tests for detecting diseases are provided to individuals. Invitae has raised $189.56 million across 11 funding rounds from investors including SoftBank Group, Orbimed and Farallon Capital Management. The company has 1,700 employees. Invitae has completed 13 acquisitions, including AltaVoice, ArcherDX and CancerGene Connect. Its chief executive, as recorded, is Sean Emerson George. Its website invitae.com draws about 439 thousand monthly visits. Invitae offers products and services including Oncology Tests, Women's Health Tests, Pediatrics and Rare Diseases Tests, Cardiology Tests, and Neurology Tests. Its focus areas include Life Sciences, Genomics, Applied Genomics and Consumer Genomics. Its competitors include Everlywell, Viome and Color; 3 of its 3 listed competitors have raised funding.
Company details
Invitae was founded in 2010 in San Francisco, United States, and operates in the genetic testing sector. Genetic tests are requested online by individuals, with saliva samples collected through assistance from doctors. Diseases are detected via analysis, and results are accessed online for sharing with healthcare providers. The platform supports home-based services focused on personal genetic health assessments.
- Headquarters San Francisco, United States
- Employees 1,700
- Founders Michele Cargill, Sean Emerson George
- Stage Public
- SectorsHealthcare
- Website category Health · Health Conditions and Concerns
- Email••••••••
- Phone•••• ••••
- Website invitae.com
- Social LinkedIn X Facebook Instagram
- Annual Revenue$516.3 M (USD)12as on Dec 31, 2022
- Net Profit-$3.11 B (USD)-720as on Dec 31, 2022
- EBITDA-$3.12 B (USD)-696as on Dec 31, 2022
- Total Equity Funding$189.56M (USD)
in 11 rounds
- Latest Funding Round$1.15B (USD), Post-IPO
Apr 2021
- InvestorsSoftBank Group
& 16 more
- Employee Count1,700
- Investments & AcquisitionsAltaVoice
& 12 more
Products & Services of Invitae
Invitae offers a comprehensive portfolio of products and services, including Oncology Tests, Women's Health Tests, Pediatrics and Rare Diseases Tests, Cardiology Tests, and Neurology Tests.
Genetic tests for cancer risks and diagnostics
Tests for genetic factors in women's health issues
Services for identifying rare genetic conditions in children
Genetic analysis for heart-related conditions
Tests for neurological disorder genetic risks
Funding Insights of Invitae
Invitae has successfully raised a total of $189.56M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $1.15 billion completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $189.56M
- Total Rounds 11
- Last Round Post-IPO — $1.15B
- First Round $29.56M
(Nov 2012)
- Investors Count 17
Latest 10 of 11 funding rounds of Invitae with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2021 | $1.15B | Post-IPO | – | – | |
| Jul 2020 | $475M | Post-IPO | – | – | |
| Sep 2019 | $350M | Post-IPO | – | – | – |
| Nov 2018 | $5M | Post-IPO | – | – | |
| Nov 2018 | $200M | Debt – Conventional | – | – | |
| Feb 2018 | $40M | Debt – Conventional | – | – | |
| Aug 2017 | $73.5M | Post-IPO | – | – | – |
| Aug 2017 | $16.08M | Post-IPO | – | – | – |
| Oct 2014 | $120M | Series F | – | The Broe Group, Decheng Capital | |
| Dec 2013 | $40M | Series E | – | – |
17 investors in total: 17 institutional.
Investors in Invitae
Invitae has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include SoftBank Group, Orbimed and Farallon Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple investment strategies are pursued by this hedge fund. | 1986 | faralloncapital.com | San Francisco, United States | |
Structured financing solutions are provided for the global healthcare industry by Oberland Capital. | 2013 | oberlandcapital.com | New York, United States | |
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
| broe.com | ||||
Venture capital firm focused on life science and technology sectors | decheng.com | Shanghai, China | ||
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com |
Investor details for Invitae
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Invitae
718 people are tracked at Invitae (297 in leadership, 9 in board & advisors, 412 in team); the tracked headcount is 1,700.
| Name | Role | Group |
|---|---|---|
Michele Cargill | Co-Founder | Leadership |
Sean Emerson George | Co-Founder & CEO | Leadership |
Adam H. Schechter | President & CEO | Leadership |
Charles Houck | Director Of Information Technology For Covance Market Access Services | Leadership |
Sandra D. Van Der Vaart | EVP, Chief Legal Officer, Chief Compliance Officer, & Corporate Secretary | Leadership |
John Ratliff | CEO, LabCorp Diagnostics | Leadership |
Kent Pearson | Director, IT Enterprise Monitoring And Operations | Leadership |
Crystal Icenhour | Microbiome & Specialty Infectious Disease Director | Leadership |
Bobbi Croy | Vice President IT | Leadership |
Libby Williams | Director - IT Infrastructure, Integration Services | Leadership |
Joseph Campo | Associate Vice President / IT Director - Client Connectivity & Support | Leadership |
Crystal Lala | Pre-clinical Med-device Director Of Operations | Leadership |
Nezabravka Tzvetanova | Business Development Director | Leadership |
Jordan Woodrick | Director Of Operations | Leadership |
Lucas Rifkin | Senior Medical Director | Leadership |
Kim Dugan | Director Specialty Analytics And Support | Leadership |
Will Stimpson | Global Executive Director Business Development - CMC | Leadership |
Julia Wang | EVP & CFO | Leadership |
Howard D. Engler | Associate Vice President | Leadership |
Amanda Kukulski | Senior Director, Data Products | Leadership |
698 more people are available in the full profile.
Complete people profiles for Invitae
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Invitae
Invitae has strategically engaged in corporate development activities, having acquired 13 companies. Notable acquisitions include AltaVoice, ArcherDX and CancerGene Connect.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Personal health data is stored, managed, and shared online. | ciitizen.com | Redwood, United States | 2017 | Sep 2021 | $325M | |
Provider of technical support services for biopharma industry | genosity.com | Iselin, United States | 2016 | Apr 2021 | $200M | |
Molecular cancer diagnostic products are developed using patented AMP technology. | archerdx.com | Boulder, United States | 2013 | Jun 2020 | $1.4B | |
Software for diagnosing rare diseases is provided using machine learning. | diploid.com | Leuven, Belgium | 2014 | Mar 2020 | $95M | |
Clinical decision support software for drug interactions is developed. | youscript.com | Seattle, United States | 2000 | Mar 2020 | $79.3M | |
Provides DNA Drug Sensitivity tests | genelex.com | Seattle, United States | 1987 | Mar 2020 | $20.7M | |
Chatbot and telemedicine platform for genetic results interpretation is provided. | cleargenetics.com | San Francisco, United States | 2016 | Nov 2019 | $50M | |
Genomic software solutions for diagnostic development are provided. | jungla.bio | San Francisco, United States | 2016 | Jul 2019 | •••• | |
Tools for single molecule detection are developed by Singular Bio. | singularbio.com | San Francisco, United States | 2012 | Jun 2019 | $55M | |
Molecular diagnostics for inherited genetic disease screening are provided. | goodstartgenetics.com | Boston, United States | 2008 | Jul 2017 | $40M |
Complete acquisition details for Invitae
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Invitae
14 dated milestones of Invitae across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Invitae is founded.
- Funding First funding round of $29.6M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Good Start Genetics.
- Acquisition Acquires Singular Bio.
- Acquisition Acquires Jungla.
- Acquisition Acquires Clear Genetics.
- Acquisition Acquires Genelex.
- Acquisition Acquires YouScript.
- Acquisition Acquires Diploid.
- Acquisition Acquires ArcherDX.
- Funding Latest funding round, Post-IPO, of $1.1B.
- Acquisition Acquires Genosity.
- Acquisition Acquires Ciitizen.
Competitors of Invitae
Invitae has 3 listed competitors in our database, 3 of them funded. They include Everlywell, Viome and Color.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| everlywell.com | 2014 | Austin, United States | $330M | 614 | At-home health tests for biomarkers, nutrition, and hormone analysis. | |
| viome.com | 2016 | Los Alamos, United States | $301.57M | 136 | Machine learning-based bioinformatics solutions for health insights are provided. | |
| color.com | 2013 | Burlingame, United States | $491.44M | 687 | Cancer care is delivered through a virtual clinic by Color. |
Detailed competitors of Invitae
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Invitae
The website of Invitae (invitae.com) receives about 439.4K visits a month and ranks #95,124 among all websites worldwide, #2,733 in Health Conditions and Concerns.
- Monthly visits439.4K
▲ 10.4% vs previous month
- Unique visitors105.6K
per month
- Global rank#95,124
among all websites
- Category rank#2,733
Health · Health Conditions and Concerns
- Bounce rate34%
- Pages per visit6.4
- Average visit3 min 20 sec
- DevicesDesktop 58% · Mobile 42%
Websites whose visitors overlap most with Invitae. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
omim.org | omim.org | 100% | #90,018 | – | |
genomicslawreport.com | genomicslawreport.com | 98% | – | ||
| ambrygen.com | 97% | 189.2K | #206,714 | View details | |
| preventiongenetics.com | 96% | 24.4K | #1,074,192 | View details | |
| nccn.org | 93% | #61,038 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Invitae
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Invitae (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Invitae
Complete news archive for Invitae
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Invitae
Invitae was founded in 2010 and raised its 1st funding round 2 years after it was founded.
Invitae is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Sean Emerson George is the CEO of Invitae, as recorded in our data. They have also founded this company.
Invitae is a funded company, having raised a total of $189.56M across 11 funding rounds to date. The company's 1st funding round was a Series E of $40M, raised on Nov 2012.
Invitae has 1,700 employees.
Annual revenue of Invitae is $516.3M as on Dec 31, 2022.
Invitae was founded in 2010 in San Francisco, United States, and operates in the genetic testing sector. Genetic tests are requested online by individuals, with saliva samples collected through assistance from doctors. Diseases are detected via analysis, and results are accessed online for sharing with healthcare providers. The platform supports home-based services focused on personal genetic health assessments.
Invitae's top competitors include Viome, Color and Everlywell.
Invitae offers Oncology Tests, Women's Health Tests, Pediatrics and Rare Diseases Tests, Cardiology Tests, and Neurology Tests.
Invitae has made 13 acquisitions, including AltaVoice, ArcherDX, and CancerGene Connect.
Invitae has 17 investors. Key investors include SoftBank Group, Orbimed, Farallon Capital Management, Driehaus, and Oxford Finance.
The website of Invitae receives about 439 thousand visits a month and ranks #95,124 among all websites worldwide.